In the Claims:

1. (Currently Amended) A compound represented by the following structural formula:



(I)

wherein

n is 2, 3, 4, 5, 6, 7 or 8;

m is 0 or 1;

p_1 and p_2 are independently of each other 0 or 1;

R_1 and R_2 are independently of each other ~~an unsubstituted or substituted aryl,~~ heteroaryl, ~~cycloalkyl,~~ heterocyclyl, ~~alkylaryl,~~ alkylheteroaryl, ~~alkylcycloalkyl~~ or alkylheterocyclyl, optionally substituted with alkyl, haloalkyl, alkoxy, halogen, hydroxyl, nitro, oxo, -CN, -COH, -COOH, amino, azido, N-alkylamino, N,N-dialkylamino, N-arylamino, N,N-diarylamino, $NHSO_2R$, -C(O)-OR, aryl, heteroaryl, cycloalkyl, alkylaryl, alkylheteroaryl, alkylheterocyclyl, alkylcycloalkyl, or aryloxy; where R is alkyl or aryl;

~~or when p_1 and p_2 are both 0, R_1 and R_2 together with the $-CH_2-N-CH_2-$ group to which they are attached can also represent a nitrogen-containing heterocyclic ring; or when at least one of p_1 or p_2 is not 0, R_1 or R_2 or both can also represent hydrogen or alkyl;~~

~~and~~ or a pharmaceutically acceptable salt~~s, solvates, hydrates, prodrugs and polymorphs~~ thereof.

2. (Original) The compound of claim 1, wherein p_1 and p_2 are both 0.

3. (Original) The compound of to claim 1, wherein p_1 and p_2 are both 1.

4. (Original) The compound of claim 1, wherein m is 0.

5. (Original) The compound of claim 1, wherein m is 1.

6. (Currently Amended) A compound represented by the following structural formula:



(II)

wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R_1 and R_2 are independently of each other ~~a hydrogen or an unsubstituted or substituted alkyl, aryl,~~ heteroaryl, ~~cycloalkyl,~~ heterocyclyl, ~~alkylaryl,~~ alkylheteroaryl, ~~alkylcycloalkyl~~ or alkylheterocyclyl, optionally substituted with alkyl, haloalkyl, alkoxy, halogen, hydroxyl, nitro, oxo, -CN, -COH, -COOH, amino, azido, N-alkylamino, N,N-dialkylamino, N-arylamino, N,N-diarylamino, $NHSO_2R$, -C(O)-OR, aryl, heteroaryl, cycloalkyl, alkylaryl, alkylheteroaryl, alkylheterocyclyl, alkylcycloalkyl, or aryloxy; where R is alkyl or aryl;

~~and~~ or a pharmaceutically acceptable salt~~s, solvates, hydrates, prodrugs and polymorphs~~ thereof.

7. (Currently Amended) A compound represented by the following structural formula:



(III)

wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R_1 and R_2 are independently of each other ~~a hydrogen or an unsubstituted or substituted~~

~~alkyl, aryl,~~ heteroaryl, ~~cycloalkyl,~~ heterocyclyl, ~~alkylaryl,~~ alkylheteroaryl, ~~alkylcycloalkyl~~ or alkylheterocyclyl, optionally substituted with alkyl, haloalkyl, alkoxy, halogen, hydroxyl, nitro, oxo, -CN, -COH, -COOH, amino, azido, N-alkylamino, N,N-dialkylamino, N-arylamino, N,N-diarylamino, $NHSO_2R$, -C(O)-OR, aryl, heteroaryl, cycloalkyl, alkylaryl, alkylheteroaryl, alkylheterocyclyl, alkylcycloalkyl, or aryloxy; where R is alkyl or aryl;

~~and~~ or a pharmaceutically acceptable salt~~s, solvates, hydrates, prodrugs and polymorphs~~ thereof.

8. (Currently Amended) A compound represented by the following structural formula:



(IV)

wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R_1 and R_2 are independently of each other ~~an unsubstituted or substituted aryl,~~ heteroaryl, ~~cycloalkyl,~~ heterocyclyl~~, alkylaryl,~~ alkylheteroaryl, ~~alkylcycloalkyl~~ or alkylheterocyclyl, optionally substituted with alkyl, haloalkyl, alkoxy, halogen, hydroxyl, nitro, oxo, -CN, -COH, -COOH, amino, azido, N-alkylamino, N,N-dialkylamino, N-arylamino, N,N-diarylamino, $NHSO_2R$, -C(O)-OR, aryl, heteroaryl, cycloalkyl, alkylaryl, alkylheteroaryl, alkylheterocyclyl, alkylcycloalkyl, or aryloxy; where R is alkyl or aryl;

~~or R_1 and R_2 together with the $-CH_2-N-CH_2-$ group to which they are attached can also represent a nitrogen-containing heterocyclic ring;~~

~~and~~ or a pharmaceutically acceptable salt~~s, solvates, hydrates, prodrugs and polymorphs~~ thereof.

9. (Currently Amended) A compound represented by the following structural formula:



(V)

wherein

n is 2, 3, 4, 5, 6, 7 or 8;

R_1 and R_2 are independently of each other ~~an unsubstituted or substituted aryl,~~ heteroaryl, ~~cycloalkyl,~~ heterocyclyl, ~~alkylaryl,~~ alkylheteroaryl, ~~alkylcycloalkyl or~~ alkylheterocyclyl, optionally substituted with alkyl, haloalkyl, alkoxy, halogen, hydroxyl, nitro, oxo, -CN, -COH, -COOH, amino, azido, N-alkylamino, N,N-dialkylamino, N-arylamino, N,N-diarylamino, $NHSO_2R$, -C(O)-OR, aryl, heteroaryl, cycloalkyl, alkylaryl, alkylheteroaryl, alkylheterocyclyl, alkylcycloalkyl, or aryloxy; where R is alkyl or aryl;

~~or R_1 and R_2 together with the $-CH_2-N-CH_2-$ group to which they are attached can also represent a nitrogen-containing heterocyclic ring;~~

~~and~~ or a pharmaceutically acceptable salt~~s, solvates, hydrates, prodrugs and polymorphs~~ thereof.

10. (Previously presented) The compound of claim 1, wherein n is 5.

11. (Previously presented) The compound of claim 1, wherein n is 6.

12. (Currently Amended) The compound of claim 1, wherein at least one of R_1 and R_2 is ~~an unsubstituted or substituted phenyl, benzyl, alkylphenyl, naphthyl, biphenyl, $-CH(Ph)_2$, $-CH=CHPh$, cyclohexyl, alkylcyclohexyl,~~ quinolinyl, alkylquinolinyl, isoquinolinyl, alkylisoquinolinyl, tetrahydroquinolinyl, alkyltetrahydroquinolinyl, tetrahydroisoquinolinyl, alkyltetrahydroisoquinolinyl, indazolyl, alkylindazolyl, benzothiazolyl, alkylbenzothiazolyl, indolyl, alkylindolyl, piperazinyl, alkyklpiperazinyl, morpholinyl, alkylmorpholinyl, piperidinyl, alkylpiperidinyl, pyridyl or alkylpyridyl, optionally substituted with alkyl, haloalkyl, alkoxy, halogen, hydroxyl, nitro, oxo, -CN, -COH, -COOH, amino, azido, N-alkylamino, N,N-dialkylamino, N-arylamino, N,N-diarylamino, $NHSO_2R$, -C(O)-OR, aryl, heteroaryl, cycloalkyl, alkylaryl, alkylheteroaryl, alkylheterocyclyl, alkylcycloalkyl, or aryloxy; where R is alkyl or aryl;

13. Cancelled.

14. Cancelled.

15. - 20. (Cancelled).

21. (Previously presented) A composition comprising a pharmaceutically effective amount of the compound of claim 1.

22. (Previously presented) A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 1, and a pharmaceutically acceptable carrier.

23. - 24. (Cancelled).

25. (Withdrawn) A method of treating cancer in a subject in need of treatment comprising administering to said subject a therapeutically effective amount the compound of claim 1, wherein said amount is effective to treat cancer in said subject.

26. (Withdrawn) The method of claim 25, wherein the cancer is selected from the group consisting of acute leukemia, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), Hairy Cell Leukemia, cutaneous T-cell lymphoma (CTCL), noncutaneous peripheral T-cell lymphoma, lymphoma associated with human T-cell lymphotrophic virus (HTLV), adult T-cell leukemia/lymphoma (ATLL), Hodgkin's disease, non-Hodgkin's lymphoma, large-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma, primary central nervous system (CNS) lymphoma, multiple myeloma, childhood solid tumors, brain tumor, neuroblastoma, retinoblastoma, Wilm's tumor, bone tumor, soft-tissue sarcoma, head and neck cancers, oral cancer, laryngeal cancer, esophageal cancer, genito urinary cancers, prostate cancer, bladder cancer, renal cancer, uterine cancer, ovarian cancer, testicular cancer, rectal cancer, colon cancer, lung cancer, breast cancer, pancreatic cancer, melanoma, skin cancers, stomach cancer, brain tumors, liver cancer, and thyroid cancer.

27. - 33. (Cancelled).

34. (Withdrawn) A method of treating a patient having a tumor characterized by proliferation of neoplastic cells, comprising the step of administering to the patient the compound of claim 1, in an amount effective to selectively induce terminal differentiation, induce cell growth arrest and/or induce apoptosis of such neoplastic cells and thereby inhibit their proliferation.

35. (Withdrawn) The method of claim 25, wherein said administering comprises administering a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier.

36. - 46. (Cancelled).